Fluxarten

Quick links to important sections

Fluxarten

Method of action: Other Nervous System Drugs

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fluxarten

Quick Facts

Property Description
Active ingredient Flunarizine (INN)
Form Capsules or Tablets (Oral administration)
Pharmacological class Selective Calcium Channel Blocker
General purpose Prophylaxis (Prevention) of recurrent conditions
Origin Synthetic, Piperazine derivative

Fluxarten is a prescription-only medicinal product containing the active component Flunarizine. It is a synthetic, single-ingredient medicine classified pharmacologically as a Selective Calcium Channel Blocker. This medication is typically utilized in chronic therapeutic strategies where the goal is long-term stability and prevention rather than the immediate relief of acute symptoms. The drug's chemical structure as a piperazine derivative is what grants it its characteristic neurovascular activity.


What Type of Medicine is Fluxarten (Flunarizine)?

Fluxarten is an oral preparation, typically supplied as capsules or tablets. Its core function places it in the pharmacological class of Selective Calcium Entry Blockers, a classification corresponding to the Anatomical Therapeutic Chemical (ATC) code N07CA03.

This classification means the medicine acts by modulating the flow of calcium ions into certain cells in the body, particularly in the brain and blood vessel walls. The medicine functions as a prophylactic agent in various neurovascular disorders. This indicates the drug's use in preventing certain recurrent neurological issues.


What is the General Function of Flunarizine?

The general function of Flunarizine is to help stabilize the body's neurovascular environment and prevent the recurrence of disruptive episodes. It accomplishes this through a dual mechanism that promotes blood vessel relaxation (vasodilation) and protects brain cells from becoming excessively stimulated. The drug is utilized for its ability to reduce the frequency and severity of recurrent neurovascular symptoms in patient populations.

Flunarizine's unique chemical structure grants it a long elimination half-life, typically ranging from several days up to two weeks on average during consistent daily use. This long half-life allows for simple, typically once-daily dosing to maintain consistent physiological stabilization required for successful long-term management. This defining characteristic means Fluxarten is fundamentally a prophylactic agent, used consistently to decrease the frequency and intensity of future events.

Regulatory References

  1. Flunarizine (LactMed)

What side effects are possible with Fluxarten?

The documented safety profile for Fluxarten (Flunarizine) is categorized according to official regulatory classifications derived from clinical evidence. The most frequently observed adverse reaction is Weight Increased, which is classified as Very Common, meaning it may affect more than 1 in 10 patients.

Reactions categorized as Common (affecting up to 1 in 10 patients) primarily involve the Nervous System and Psychiatric system-organ classes. These include Somnolence (drowsiness or fatigue), Depression, Increased Appetite, and Rhinitis. Somnolence is often noted to occur more prominently at the start of treatment.

A central safety concern highlighted in regulatory documents is the potential for Serious Adverse Reactions that can lead to treatment discontinuation. These include the emergence of Extrapyramidal Symptoms (movement disorders like tremor or rigidity) and significant Depression. Patients require regular observation, particularly during chronic maintenance treatment, to ensure early detection of these issues.


Safety Considerations and Restrictions

The official product information specifies heightened risk for certain patient groups. Older adults (aged 65 years and older) are considered particularly susceptible to developing Extrapyramidal Symptoms. Caution is also required for patients with hepatic (liver) impairment.

Fluxarten is formally Contraindicated and must not be used in individuals with a history of Depressive Illness or pre-existing Parkinson's Disease or other Extrapyramidal Disorders. Excessive sedation can result when this medicine is used simultaneously with central nervous system depressants, such as alcohol or tranquilizers. This restriction reflects the medicine's documented risk profile within the Nervous System and Psychiatric system-organ classes.

Overdose and Emergency Response

In the event of a suspected or confirmed overdose with Flunarizine (Fluxarten), official regulatory guidance mandates the immediate action to contact a doctor or local hospital. Urgent medical treatment is required following the ingestion of amounts exceeding the prescribed dose.

Documented Clinical Manifestations

Official prescribing information identifies several clinical manifestations that may occur in acute overdosage, with reported ingestions reaching up to 600 mg. These manifestations primarily involve effects on the Central Nervous System and the cardiovascular system. Specific symptoms reported are sedation (drowsiness), agitation (restlessness), and confusion. An observed cardiovascular sign in overdosage cases is tachycardia (a rapid heart rate). Asthenia (physical weakness) is also listed as a potential manifestation.

Official Management Procedures

Regulatory documents state that no specific antidote is known for Flunarizine overdosage. Consequently, treatment consists of symptomatic and supportive measures. Officially described procedural steps may include interventions such as gastric lavage or the administration of activated charcoal, if considered appropriate by healthcare professionals. No population-specific differences in the severity or management of acute overdose have been explicitly documented in the official prescribing information for the elderly or those with underlying conditions.

Therapeutic Uses of Fluxarten

What Fluxarten Treats: Main Uses and Benefits

Fluxarten is considered relevant for symptomatic management in clinical settings that involve acute or unstable symptom patterns. The active ingredient is utilized for the prophylaxis of migraine and the management of vertigo. The medicine is commonly used when short-term symptomatic assistance is needed to help with acute or fluctuating symptom patterns.


Easing Periods of Heightened Discomfort

This medicine is commonly used to help with episodic or fluctuating manifestations like certain types of headaches and dizziness. Fluxarten assists with symptomatic management during phases of increased distress or discomfort. The medicine supports the patient during difficult episodes by easing distress and may help patients cope more steadily with symptom fluctuations.

“Fluxarten is relevant in contexts marked by increased discomfort or tension, supporting general well-being during symptomatic phases.”

Quick Fact: Relief for Physical Discomfort


Supportive Management of Acute Symptomatic Needs

Fluxarten is applied across domains where additional symptomatic support is needed, such as when symptom clusters become more noticeable during periods of increased physiological stress. This use is relevant in contexts where short-term symptom stabilization is important when symptoms are momentarily overwhelming. The therapeutic domains of use are generally considered relevant for conditions involving recurrent or episodic manifestations of symptoms related to heightened physiological activity.

Eligibility and Restrictions for Use

Fluxarten (Flunarizine) eligibility is strictly defined by regulatory criteria concerning pre-existing conditions and specific population groups.

Absolute Contraindications

The medicine must not be used in patients with a current depressive illness or a history of recurrent depression. It is also contraindicated for individuals with pre-existing symptoms of Parkinson's Disease or other extrapyramidal disorders, as stated in official regulatory documentation.

Age and Physiological Restrictions

Use is generally established for adult patients (18 years and older). The medicine is not recommended for the pediatric population (under 18 years) because its safety and efficacy have not been established. Older adults (65 years and older) require special consideration and should be used with caution.

Comorbidity and Reproductive Status

Fluxarten should not be administered during pregnancy, and women must not breastfeed while using this medicine due to safety concerns documented in regulatory sources. Caution is also advised for patients with Liver Function Disorders due to how the drug is metabolized, and individuals with certain hereditary sugar intolerances should not take the tablet formulation.

What should I know about interactions with other medicines?

Fluxarten (Flunarizine) may interact with certain medicines and substances, primarily due to its effects on the central nervous system (CNS) and its metabolism in the liver. These interactions can enhance side effects, potentially increase the concentration of the drug, or in rare cases, reduce the efficacy of other medications.

Clinically Significant Interactions

Interacting Product Category Potential Effect / Mechanism Severity / Regulatory Advice
CNS Depressants (e.g., Sedatives, Tranquilizers, Hypnotics, Anti-anxiety medicines like benzodiazepines, Muscle Relaxants, Alcohol) Enhanced Central Depression: Co-administration leads to additive sedative effects, increasing drowsiness and potentially impairing alertness and motor function. Use with Caution: Monitoring is required; patients should be advised to limit or avoid alcohol.
Enzyme Inducers (e.g., Carbamazepine, Phenytoin) Decreased Fluxarten Levels: These medicines accelerate the hepatic metabolism of Fluxarten, potentially reducing its concentration in the blood and diminishing its therapeutic effectiveness. Monitor Therapy: Dose adjustments for Fluxarten may be necessary.
Oral Hormonal Contraceptives Galactorrhea: There have been reports of galactorrhea (abnormal breast milk production) in women using oral contraceptives concomitantly. Monitor Therapy: Patient observation is advised, particularly during the initial months of treatment.

No relevant pharmacokinetic interactions have been widely reported for many other common medications. However, due to its metabolic pathway (CYP2D6), co-administration with strong inhibitors of this enzyme could theoretically increase the concentration of Fluxarten, increasing the risk of adverse effects. Patients should inform their healthcare provider of all prescription, over-the-counter, and herbal products currently being taken.

Mechanism of Action

Stabilizing Neuronal and Vascular Activity

The molecule is classified as a selective calcium entry blocker, acting through the blockade of voltage-dependent Ca^2+ channels in neuronal and vascular smooth muscle cells. This non-competitive blockade prevents the massive influx of calcium ions ( Ca^2+) that is induced by excessive cellular stimulation. By limiting this key molecular step, the molecule modulates systems where targeted pathway adjustment influences cellular hyper-responsiveness.


Integrated Neurovascular Modulation

The molecule establishes its multi-target action that extends beyond Ca^2+ channels to include the antagonism of histamine H1 and dopamine D2 receptors, alongside the inhibition of intracellular Calmodulin. This integrated mechanism modifies early molecular steps that shape systemic consequences, involving a decrease in neuronal hyper-excitability and the induction of blood vessel relaxation (vasodilation). These actions contribute to the regulation of neurovascular balance.

Dosage and Administration Information

How to Use Fluxarten: Official Administration Guidelines

The administration of Fluxarten (Flunarizine) follows a structured protocol designed to manage its use over time. The medicine is supplied as tablets or capsules and is designated exclusively for oral administration.

It is taken once daily (QD), and standard guidelines describe dosing at night before going to bed. The medication may be administered with or without food.


Official Dosing and Regimens

The established dosage varies by age group, and the maximum recommended daily dose for adults is 10 mg.

Population Initial Daily Dose Key Instruction
Adults (18–64 years) 10 mg daily Maximum dose for this group is 10 mg/day.
Older Adults (ge 65 years) 5 mg daily A lower starting dose is recommended.

Procedural Course Structure

The usage of Fluxarten is divided into distinct, time-limited phases, establishing a defined course of use:

  1. Initial Assessment Period: The medication should be taken daily for 2 months to determine a response before concluding that the patient is a non-responder.
  2. Maintenance Phase: For patients who respond well, the dose is often reduced (e.g., to 5 mg) or administered as an intermittent regimen that includes two consecutive drug-free days every week.
  3. Mandatory Interruption: The maintenance treatment must be interrupted after 6 months. Continued therapy is only re-initiated if the patient's condition relapses.

Recent Clinical Evidence

Fluxarten: Recent Clinical Evidence

Evidence for Use in Migraine Prophylaxis

Research exploring Fluxarten was studied for use in recurrent migraine episodes, relying on numerous Randomized Controlled Trials (RCTs). Adult patients with episodic migraine were observed over periods of 3 to 4 months. Researchers examined the mean monthly attack frequency, the responder rate, and changes in headache-related disability scores. Systematic reviews report how symptoms evolved in observed populations when compared to placebo or other active comparator treatments. Findings indicate research provides insight into short-term changes in attack patterns. Limitations include the fact that many key trials are older, and that long-term effects are not fully established.

Evidence for Use in Vestibular Migraine

The research exploring conditions characterized by fluctuating or episodic manifestations of dizziness and vertigo differs in its study type and volume compared to that for migraine prophylaxis. Research consists mainly of Systematic Reviews and smaller observational studies. Studies examined adults with Vestibular Migraine over 3 to 6 months, focusing on recurrent vertigo frequency and dizziness handicap. Certainty remains low due to heterogeneity and small sample sizes; research findings were often mixed.

Long-Term Research and Durability of Study Findings

Controlled trials were designed to monitor symptom patterns over relatively short time intervals (three to four months). Long-term effects are not fully established for either studied indication. Research has explored the medicine in observational settings for longer periods, but comparative evidence is lacking regarding long-term outcomes.

Evidence in Specific Patient Groups

Fluxarten was observed in Pediatric populations with migraine. Systematic reviews note that sample sizes were modest and the evidence quality varies across studies for young people. Limited data are available for other groups, such as older adults or individuals with comorbidities.

What Research Reports as Uncertain or Limited

The research exploring Fluxarten presents specific limitations, including the reliance on many older trials. Data are still emerging for certain clinical applications, and across all indications, the follow-up durations were limited. The research highlights what is known—and what is still uncertain—about the findings from research.

Key Studies & References

  1. Prophylactic treatments for vestibular migraine: a systematic review and network meta-analysis of randomized clinical trials

Frequently Asked Questions (FAQ)

Common questions about Fluxarten (FAQ)

Q: Is Fluxarten the same type of medicine as [similar drug name]?

A: Official information classifies Fluxarten (Flunarizine) as a selective calcium entry blocker and a diphenylpiperazine derivative. Other medicines may belong to the broader class of calcium entry blockers, but this specific combination of chemical structure and action is what defines Fluxarten.

Q: How quickly do people typically notice an effect from Fluxarten?

A: Fluxarten is used for the prevention of recurrent conditions, not for immediate relief. Studies indicate that it takes time for the medicine to build up consistently in the body, with a steady level typically reached after approximately five to eight weeks of consistent daily use. The full assessment of benefit takes time, as noted in the official usage protocols.

Q: What is the average duration of action for a dose of Fluxarten?

A: The medicine is noted for its long duration of effect, which supports its once-daily dosing. Clinical pharmacological studies indicate the medicine has a long elimination half-life, averaging about 18 to 19 days when used consistently. This characteristic supports its intended use for long-term management.

Q: Can Fluxarten affect my sleep patterns?

A: Drowsiness, medically referred to as Somnolence, is listed as a common side effect in regulatory documents. This potential effect may influence sleep patterns. The official product information notes that the medicine is often recommended to be taken at night before going to bed.

Q: Is it normal to feel slightly dizzy when starting Fluxarten?

A: Some official reports include dizziness as a possible side effect, particularly when treatment is initiated. The presence of dizziness and similar effects often results in official warnings regarding activities that require full alertness.

Q: Do the side effects of Fluxarten usually go away over time?

A: Official documentation notes that drowsiness (Somnolence), a common side effect, may be more prominent at the start of treatment. This observation is specific to drowsiness; official information provides no general statement about all side effects lessening over time.

Q: What happens if I forget to take a dose of Fluxarten?

A: Official guidelines outline a procedure where a missed dose may be taken when remembered, provided it is not close to the next scheduled dose. However, if it is already close to the time of the next scheduled dose, the regulatory advice is to skip the missed dose entirely and avoid taking a double amount.

Q: Is there a maximum amount of time a person can safely take Fluxarten?

A: The use of Fluxarten is structured around defined periods of use for recurrence prevention. According to regulatory documents, maintenance treatment must be interrupted after 6 months. Continued therapy is only re-initiated if the patient's condition relapses after this mandatory interruption.

Q: Does Fluxarten have any known interactions with birth control pills?

A: Yes, official labeling notes a potential interaction. There have been reports of galactorrhea (abnormal breast milk production) in women who use oral hormonal contraceptives at the same time as this medicine.

Q: Does research indicate any differences in how Fluxarten works in men versus women?

A: Available research evidence is limited for specific population groups. Systematic reviews that have examined the medicine in different patient populations have not specifically reported established differences in how male and female populations respond to treatment.

Q: Can I stop taking Fluxarten suddenly, or does it need to be tapered off?

A: Due to the medicine's long half-life, official labeling emphasizes that any decision to discontinue the medicine should be managed under the guidance of a healthcare professional. Abrupt cessation is not typically described in official materials.

Q: What is the risk of a serious allergic reaction to Fluxarten?

A: As is described for nearly all medications, the possibility of a serious allergic reaction, or hypersensitivity, is noted in official drug information. Patient safety guidance states that symptoms of a severe reaction require immediate emergency medical attention.

Q: What distinguishes Fluxarten from other drugs in its class?

A: Fluxarten is primarily classified as a selective calcium entry blocker, but official documents describe its multi-target action. This includes the additional antagonism of histamine H1 and dopamine D2 receptors, and the inhibition of intracellular Calmodulin.

Q: Can Fluxarten be used by people with a history of heart problems?

A: Official drug information advises that caution is required for patients who have a history of heart problems, such as heart failure. This consideration is noted due to the potential for certain documented effects on the cardiovascular system.

Q: What are the official warnings about driving or operating machinery while on Fluxarten?

A: Official warnings state that because this medicine can cause side effects like drowsiness or dizziness, activities requiring full alertness, such as driving or operating heavy machinery, should be approached with caution or avoided.

Q: Is there a link between Fluxarten and changes in mood or anxiety levels?

A: Official documents describe Depression as both a serious adverse reaction and list a history of depressive illness as an absolute contraindication for use. Observation and monitoring for significant mood changes are advised for patients using this medicine.

Q: Are there specific instructions for what to do in case of an accidental overdose of Fluxarten?

A: Official regulatory guidelines emphasize that a suspected or accidental overdose requires the patient to immediately seek emergency medical treatment or contact a poisons control center. This is necessary due to the potential for serious health complications.

Q: What kind of stomach issues are sometimes linked to Fluxarten use?

A: Some regional product information reports that gastrointestinal symptoms have been observed in certain patients. These can include issues such as nausea, vomiting, abdominal pain, or constipation.

Q: What foods or supplements should be avoided while taking Fluxarten?

A: Regulatory documents primarily focus on drug-drug interactions. However, because this medicine is metabolized by certain liver enzymes, caution is often advised with products, like grapefruit, that are known to potentially interfere with these enzymes.

Q: Is it safe to drink alcohol in moderation while on Fluxarten?

A: Official guidelines describe the need to limit or avoid alcohol completely while using this medicine. This is because alcohol can enhance the drug's effect on the central nervous system, which may increase the risk of drowsiness and impairment.

Q: What if Fluxarten doesn't seem to be working for me after several weeks?

A: Official usage protocols specify a required assessment period. If the condition has not improved significantly after the first two months of consistent use, the treatment is generally recommended to be discontinued and requires the involvement of a healthcare professional for the next steps.

How should Fluxarten be stored and disposed of?

How to Store and Dispose of Fluxarten

Fluxarten (Flunarizine) must be stored and handled according to the specific conditions defined in the official regulatory labeling to maintain the product's stability.

Storage Requirements

The medicine must be stored at controlled room temperature, generally below 30 C (86 F). It is essential to keep the product in its original container and ensure it is protected from moisture and light. The label specifies that you must not freeze the medicine or store it in high-humidity areas, such as a bathroom.

Child Safety

As with all medications, Fluxarten must be stored out of the sight and reach of children.

Disposal Instructions

To prevent environmental contamination, do not dispose of unused or expired Fluxarten via wastewater or household waste. All unused or waste medication must be handled according to local regulations or returned to a designated take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fluxarten found in:

A-Z Index: